These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 10689875

  • 21. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Knipp S, Hildebrand B, Kündgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U.
    Cancer; 2007 Jul 15; 110(2):345-52. PubMed ID: 17559141
    [Abstract] [Full Text] [Related]

  • 22. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
    Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T.
    Cancer; 2007 Mar 01; 109(5):907-14. PubMed ID: 17285599
    [Abstract] [Full Text] [Related]

  • 23. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, Tu MF, Wang XL, Hao YS, Yang TY, Yang CL.
    Chin Med J (Engl); 2004 Jul 01; 117(7):963-7. PubMed ID: 15265365
    [Abstract] [Full Text] [Related]

  • 24. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P, Vítek A, Michalová K, Zemanová Z, Lukásová M.
    Vnitr Lek; 2003 Mar 01; 49(3):174-80. PubMed ID: 12728590
    [Abstract] [Full Text] [Related]

  • 25. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
    Matsouka P, Pagoni M, Zikos P, Giannakoulas N, Apostolidis I, Asprogeraka T, Arvanitopoulou E, Spanoudakis E, Kotsianidis I, Tsatalas K, Papaioannou M, Marinakis T, Skandali A, Viniou N, Yataganas X, Bakiri M.
    Ann Hematol; 2006 Apr 01; 85(4):250-6. PubMed ID: 16416114
    [Abstract] [Full Text] [Related]

  • 26. Survival of elderly patients with acute myeloid leukemia.
    Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, De Paoli L, Di Bona E, Invernizzi R, Marmont F, Petti MC, Rigolin G, Ronco F, Spadano A, Tosti ME, Visani G, Mele A, Mandelli F.
    Haematologica; 2004 Mar 01; 89(3):296-302. PubMed ID: 15020267
    [Abstract] [Full Text] [Related]

  • 27. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
    Bolaños-Meade J, Guo C, Gojo I, Karp JE.
    Leuk Res; 2004 Jun 01; 28(6):571-7. PubMed ID: 15120933
    [Abstract] [Full Text] [Related]

  • 28. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
    Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG, Children's Oncology Group.
    Pediatr Blood Cancer; 2007 Jul 01; 49(1):17-22. PubMed ID: 16856158
    [Abstract] [Full Text] [Related]

  • 29. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 30. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J, Shao Z, Liu H, Li K, Song L, Zhang Y, Zheng Y, Chen G, Chu Y, He H, Zhao M, He G, Feng B, Hao Y, Yang T, Yang C.
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul 15; 22(7):351-4. PubMed ID: 11877096
    [Abstract] [Full Text] [Related]

  • 31. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B, Gao YR, Wang C, Yan SK, Cai Q, Jiang JL, Yang J, Bai HT, Zhao M, Zhao CX.
    Ai Zheng; 2006 Aug 15; 25(8):1007-12. PubMed ID: 16965684
    [Abstract] [Full Text] [Related]

  • 32. [Treatment results of acute leukemia in elderly patients: analysis of 61 consecutive patients in a single institution].
    Sakai M, Takeyama H, Kojima Y, Shimokawa T.
    Gan To Kagaku Ryoho; 2008 Feb 15; 35(2):239-44. PubMed ID: 18281758
    [Abstract] [Full Text] [Related]

  • 33. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
    Doubek M, Palasek I, Brychtova Y, Buchtova I, Mayer J.
    Neoplasma; 2005 Feb 15; 52(5):411-4. PubMed ID: 16151586
    [Abstract] [Full Text] [Related]

  • 34. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
    Ferrero D, Campa E, Dellacasa C, Campana S, Foli C, Boccadoro M.
    Haematologica; 2004 May 15; 89(5):619-20. PubMed ID: 15136232
    [Abstract] [Full Text] [Related]

  • 35. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
    Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, Pigneux A, Quesnel B, Witz F, Thépot S, Ugo V, Terre C, Recher C, Tavernier E, Hunault M, Esterni B, Castaigne S, Guilhot F, Dombret H, Vey N, Acute Leukemia French Association, Groupe Ouest-Est des leucémies et autres maladies du sang (GOELAMS), Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup.
    J Clin Oncol; 2009 Oct 01; 27(28):4747-53. PubMed ID: 19720919
    [Abstract] [Full Text] [Related]

  • 36. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C.
    J Clin Oncol; 2007 Jan 20; 25(3):292-300. PubMed ID: 17159192
    [Abstract] [Full Text] [Related]

  • 37. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E.
    Cancer; 2006 Mar 01; 106(5):1099-109. PubMed ID: 16435387
    [Abstract] [Full Text] [Related]

  • 38. Treatment of acute myelogenous leukemia with outpatient azacitidine.
    Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.
    Cancer; 2006 Oct 15; 107(8):1839-43. PubMed ID: 16967444
    [Abstract] [Full Text] [Related]

  • 39. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N.
    Ann Hematol; 2005 Dec 15; 84 Suppl 1():61-6. PubMed ID: 16270213
    [Abstract] [Full Text] [Related]

  • 40. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
    Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S.
    J Clin Oncol; 2005 Dec 20; 23(36):9387-93. PubMed ID: 16314618
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.